| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
41,560,000 |
| Market
Cap: |
260.58(M) |
| Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
| 52
Week Range: |
$3.61 - $10.69 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
| Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
| Total People Bought |
0 |
0 |
3 |
3 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
118,082 |
130,582 |
172,562 |
368,410 |
| Total Sell Value |
$980,899 |
$1,074,708 |
$1,440,488 |
$3,484,755 |
| Total People Sold |
5 |
6 |
6 |
6 |
| Total Sell Transactions |
6 |
7 |
8 |
21 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-29 |
4 |
S |
$17.81 |
$6,608 |
D/D |
(371) |
63,240 |
|
-25% |
|
| Freitag Gregory Gene |
Director |
– • – |
2020-12-29 |
4 |
S |
$17.81 |
$16,314 |
D/D |
(916) |
248,345 |
|
-25% |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,250 |
11,669 |
|
- |
|
| Billet Isabelle |
Chief Strategy and BD Officer |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
10,145 |
|
- |
|
| Martinez Maria D. |
Chief Human Resources Officer |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
5,232 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
28,329 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
8,800 |
677,599 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
11,691 |
|
- |
|
| Scopelianos Angelo |
VP Research & Development |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
6,096 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
1,500 |
63,611 |
|
- |
|
| Freitag Gregory Gene |
Director |
– • – |
2020-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,300 |
249,261 |
|
- |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-12-23 |
4 |
OE |
$4.81 |
$93,194 |
D/D |
19,375 |
666,094 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-22 |
4 |
AS |
$17.19 |
$4,796 |
D/D |
(279) |
26,029 |
|
9% |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-12-21 |
4 |
S |
$16.42 |
$20,936 |
D/D |
(1,275) |
646,719 |
|
-13% |
|
| Freitag Gregory Gene |
Director |
– • – |
2020-12-21 |
4 |
S |
$16.42 |
$6,223 |
D/D |
(379) |
245,076 |
|
-13% |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-21 |
4 |
S |
$16.42 |
$2,414 |
D/D |
(147) |
62,111 |
|
-13% |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-21 |
4 |
S |
$16.42 |
$1,576 |
D/D |
(96) |
26,308 |
|
-13% |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-12-21 |
4 |
S |
$16.42 |
$7,898 |
D/D |
(481) |
6,419 |
|
-13% |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-12-21 |
4 |
S |
$16.42 |
$1,576 |
D/D |
(96) |
8,893 |
|
-13% |
|
| Zaderej Karen L. |
CEO |
• • – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,125 |
647,994 |
|
- |
|
| Freitag Gregory Gene |
Director |
– • – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
925 |
245,455 |
|
- |
|
| Devinney Erick Wayne |
VP, Clinical&Translational Sc |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
575 |
62,258 |
|
- |
|
| Donovan Michael Patrick |
VP Operations |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
375 |
26,404 |
|
- |
|
| Mariani Peter J |
Chief Financial Officer |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
1,900 |
6,900 |
|
- |
|
| Friedman Mark Louis |
VP,Regulatory & Quality |
• – – |
2020-12-18 |
4 |
A |
$0.00 |
$0 |
D/D |
375 |
8,989 |
|
- |
|
529 Records found
|
|
Page 11 of 22 |
|
|
0.16 (2.62%) 
